Dopaminergic Mechanisms in Depression and Antidepressant Drug Effects

Česká verze

Authors: A. Šulcová
Authors place of work: Farmakologický ústav LF MU, Brno vedoucí prof. MUDr. A . Šulcová, CSc.
Published in the journal: Čes. a slov. Psychiat., 104, 2008, No. 1, pp. 18-21.
Category: Souborné referáty

Summary

Both experimental and clinical studies are continuously bringing data suggesting a decreased activity of not only serotonergic and adrenergic but also of dopaminergic brain functioning. This corresponds well with successful therapy of depression with drugs acting either as agonists at postsynaptic dopamine receptors or inhibitors of dopamine reuptake.

Key words:
neurotransmitter dopamine, depression, mechanisms of antidepressants.

Zdroje

1. Allard, P., Norlen M.: Caudate nucleus D2 receptors in depressed suicide victims. Neuropsychobiology, 44, 2001, pp. 70-73.

2. Asberg, M., Thoren, P., Traskman, L., Bertilsson, L., Ringberger, V.: Serotonin depression -⁠ a biochemical subgroup within the affective disorders? Science, 191 (4226), 1976, pp. 478-80.

3. Berk, M., Dodd, S., Kauer-Sant’anna, M., Malhi, G. S., Bourin, M., Kapczinski, F., Norman, T.: Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl., 434, 2007, pp. 41-49.

4. Bonci, A., Hopf, F. W.: The dopamine D2 receptor: New surprises from an old friend. Neuron, 47, 2005, 3, pp. 335-338.

5. Brown, A. S., Gershon, S.: Dopamine and depression. J. Neural. Transm., 91, 1993, pp. 75-109.

6. Brugue, E., Vieta, E.: Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 2007, 1, pp. 275-282.

7. Dailly, E., Chenu, F., Renard, C. E.: Dopamine, depression and antidepressants. Fundamental & Clin.l Pharmacol., 18, 2004, pp. 601-607.

8. Di Chiara, G., Loddo, P., Tanda, G.: Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biol. Psychiatry, 46, 1999, 12, pp. 1624-1633.

9. Di Matteo, V., De Blasi, A., Di Giulio, C., Esposito, E.: Role of 5-HT2C receptors. Trends Pharmacol. Sci., 22, 2001, 5, pp. 229-232.

10. Dunlop, B.W., Nemeroff, Ch. B.: The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry, 3, 2007, pp. 327-337.

11. Elhwuegi, A. S.: Central monoamines and their role in major depression. Progress Neuro-Psychopharmacol. Biol. Psychiatry, 28, 2004, 3, pp. 435-451.

12. Engstrom, G., Alling, C., Blennow, K. et al.: Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters -⁠ Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol., 9, 1999, 5, pp. 399-405.

13. Fiorino, D. F., Coury, A., Phillips, A. G.: Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. J. Neurosci., 17,1997, 12, pp. 4849-4855

14. Foley, K. F., DeSanty K. P., Kast, R. E.: Bupropion: pharmacology and therapeutic applications. Expert Rev Neurotherapeut, 6, 2006, pp. 1249-1265.

15. Garattini, S.: Pharmacology of amineptine, an antidepressant agent acting on thedopaminergic system: a review. Int. Clin. Psychopharmacol., 12, Suppl 3, 1997, pp. S15-S19.

16. Hamner, M. B., Diamond, B. I.: Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: A pilot study. Psychiatry Res., 64, 1996, 3, pp. 209-211.

17. Hejny, S. E., Lucki, I., Gatto, G., Singh, A., Thornley, C., Matasi, J., Kong, N., Smith, J. E., Davies, H. M. L., Dworkin, S. I.: Potential antidepressant. Effects of novel tropane compounds, selective for serotonin or dopamine transporters. J. Pharmacol. Exp. Therap., 282, 1997, 21, pp. 727-733.

18. Kapur, S., Mann, J. J.: Role of the dopaminergic system in depression. Biol. Psychiatry, 32, 1992, 1, pp. 1-17.

19. Kerwin, R.: From pharmacological profiles to clinical outcomes. Int. Clin. Psychopharmacol., 15, Suppl 4, 2000, pp. S1-S4.

20. Klimek, V., Schenck, J. E., Han, H., Stockmeier, C. A., Ordway, G. A.: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry, 52, 2002, pp. 740-748.

21. Koob, G F.: Hedonic valence, dopamine, and motivation. Mol. Psychiatry, 1, 1996, pp. 186-189.

22. Lammers, C. H., Diaz, J., Schwartz, J. C., Sokoloff, P.: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry, 5, 2000, pp. 378–388.

23. Lapin, I. P., Oxenkrug, G. F.: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet, 1, (7586), 1969, pp. 132-136.

24. Lemke, M. R.: Antidepressant effects of dopamine agonists. Experimental and clinical findings. Nervenarty, 78, 2007, 1, pp. 31-38.

25. Levant, B.: The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev., 49, 1997, pp. 231-252.

26. McLean, A., Rubinsztein, J., Robbins, T., Sahakian, B.: The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. Psychopharmacol., 171, 2004, pp. 286-297.

27. Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle S. et al.: The effect of paroxetine on 5-HT2A receptors in depression: An [18F]setoperone iImaging Study. Am. J. Psychiatry, 158, 2001, 1, pp. 78-85.

28. Muscat, R., Papp, M., Willner, P.: Antidepressant-like effects. of dopamine agonists in an animal model of depression. Biol. Psychiatry, 31, 1992, pp. 937-946.

29. Ossowska, G., Nowak, G., Klenk-Majewska, B., Danilczuk, Z., Zebrowska-Lupina, I.: Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats. Polish J. Pharmacol., 54, 2002, 2, pp. 89-93.

30. Pani, L., Gessa, G. L.: Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure. Int. J. Clin. Pharmacol. Res., 17, 1997, 2-3, pp. 55-58.

31. Papakostas, G. I.: Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol., 16, 2006, pp. 391-402.

32. Park, S. K., Nguyen, M. D., Fischer, A., Luke, M. P. et al.: Par-4 links dopamine signaling and depression. Cell, 122, 2005, 2, pp. 275-287.

33. Rampello, L., Nicoletti, G., Rafaele, R.: Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatrica Scand., 84, 1991, pp. 552-554.

34. Randrup, A., Braestrup, C.: Uptake Inhibition of biogenic amines by newer antidepressant drugs: Relevance to the dopamine hypothesis of depression. Psychopharmacol., 53, 1997, pp. 309-314.

35. Robbins, T. W., Everitt, B. J.: Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology, 6, 1996, pp. 228-236.

36. Roy, A., Pickar, D., Dejong, J. et al.: Norepinephrine and its metabolites in cerebrospinal-fluid, plasma, and urine –⁠ relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch. Gen. Psychiatry, 45, 1988, 9, pp. 849-857.

37. Roy, A., Karoum, F., Pollack, S.: Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch. Gen. Psychiatry, 49, 1992, 6, pp. 447-450.

38. Saxon, A. J.: Dopamine and depression. Arch. Gen. Psychiatry, 64, 2007, 9, pp. 1101-1101.

39. Scatton, B., Claustre, Y., Cudennec A.: Review. Int. Clin. Psychopharmacol., 12 Suppl 2, 1997, pp. S29-S36.

40. Schildkraut, J. J., Gordon, E. K., Durell, J.: Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J. Psychiatr. Res., 3, 1965, 4, pp. 213-28

41. Schoemaker, H., Claustre, Y., Fage, D.: J. Pharmacol. Exp. Therap., 280, 1997, 1, pp. 83-97.

42. Seeman, P., Van Tol, H. H.: Trends pharmacol. Sci., 15, 1994, pp. 264-270.

43. Sokoloff, P., Diaz, J., Le Foll, B., Guillin, O., Leriche, L., Bezard, E., Gross, C.: CNS & Neurol. l Disorders Drug Torgets, 5, 2006, pp. 25-43.

44. Stahl S. M.: Essential psychopharmacology neuroscientific basis and practical applications. Cambridge University Press, 2000.

45. Stahl S. M.: V: The Prescriber´s guide –⁠ antidepressants. Cambridge University Press, 2006, pp. 171-178.

46. Syvalahti, E., Penttila, J., Majasuo, H., Palvimaki, E .P., Laakso, A., Hietala, J.: Pharmacopsychiatry, 39, 2006, 1, pp. 1-8.

47. Willner, P.: Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology, 134, 1997, 4, pp. 319-329.

48. Willner, P., Hale, A. S., Argyropoulosc, S.: Dopaminergic mechanism of antidepressant action in depressed patients. J. Affect. Disorders, 86, 2005, 1, pp. 37-45.